Your browser doesn't support javascript.
loading
Chemopreventive effect of celecoxib in gastric cancer.
Futagami, S; Suzuki, K; Hiratsuka, T; Shindo, T; Hamamoto, T; Ueki, N; Kusunoki, M; Miyake, K; Gudis, K; Tsukui, T; Sakamoto, C.
Affiliation
  • Futagami S; Third Department of Internal Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, 113-8602, Japan. seiji-f@nms.ac.jp
Inflammopharmacology ; 15(1): 1-4, 2007 Feb.
Article in En | MEDLINE | ID: mdl-17323186
ABSTRACT
COX (cyclooxygenase) is one of the key enzymes involved in the synthesis of a variety of prostaglandins (PGs), some of which have been strongly linked to inflammation. One of its two well-known isoforms, COX-2, is an inducible enzyme whose induction and expression is dynamically regulated by growth factors, mitogens, and tumor promoters. Several animal and clinical studies have reported the chemopreventive effect of celecoxib, a selective COX-2 inhibitor; and in particular, a few studies have shown that celecoxib prevents the development of gastric cancer. Administration of celecoxib also showed increases in cardiovascular risk and disruption of renal physiology. Therefore, studies hoping to clarify how selective COX-2 inhibitors modulate gastric cancer must keep in mind that coxibs have also been linked to serious cardiovascular events and disruption of renal physiology.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Stomach Neoplasms / Sulfonamides / Cyclooxygenase 2 Inhibitors Limits: Animals / Humans Language: En Journal: Inflammopharmacology Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2007 Document type: Article Affiliation country: Japan
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Stomach Neoplasms / Sulfonamides / Cyclooxygenase 2 Inhibitors Limits: Animals / Humans Language: En Journal: Inflammopharmacology Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2007 Document type: Article Affiliation country: Japan